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DEAR EDITOR, Psoriasis is a prevalent chronic inflammatory disease associated with comorbidities, 
e.g. cardiometabolic diseases, inflammatory bowel disease, and depression that may share an 
inflammatory origin.1 Smoking increases the risk of psoriasis and the disease has also been linked to 
chronic obstructive pulmonary disease (COPD) and asthma, with evidence of shared inflammatory 
cytokine-mediated mechanisms.2-4 Moreover, subjects with psoriasis display increased risk of 
infections, especially respiratory infections including pneumonia.1, 5 However, only a small single-
center study of pulmonary function in subjects with psoriasis is available.6 
 
We performed a cross-sectional study of spirometric values in individuals with self-reported psoriasis 
compared to controls that participated in the Danish General Suburban Population Study (GESUS).7 A 
total of 20422 individuals >20 years including 1173 (5.7%) with psoriasis and 19249 in the 
comparison group underwent pulmonary function test with use of a hand-held spirometer 
(MicroLoop, Micro Medical Ltd, Kent. UK). Forced expiratory volume in the first second (FEV1) and 
forced vital capacity (FVC) were measured in percentages of expected reference values corrected for 
height, age and sex, and the FEV1/FVC ratio was calculated.8 Psoriasis, shortness of breath, and prior 
pneumonia were identified by the questions ‘do you suffer from or have you suffered from 
psoriasis?’, ‘are you frequently bothered by shortness of breath?’, and ‘did you suffer from 
pneumonia that entailed medical attention and/or sickness leave within the last 10 years?’, 
respectively. The study conformed with the Helsinki Declaration and was approved by the regional 
ethical committee (SJ-113, SJ-114, SJ-191) and the Danish Data Protection Agency. 
 
Characteristics of the two groups are shown in Table 1. Specifically, mean body mass index (BMI) 
was higher and smoking, and frequent shortness of breath or prior pneumonia within the last 10 
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index (BMI) and high sensitivity C-reactive protein (hs-CRP) levels. Increased risk of shortness of 
breath or pneumonia within the last 10 years remained significantly increased after adjustment for 
smoking. Relative to the comparison group without psoriasis, FEV1 in percent of expected values 
(93.2±16.8 vs. 94.9±16.4%; p<0.001) and the FEV1/FVC ratio (0.76±0.09 vs. 0.77±0.08; p<0.001) were 
reduced in the psoriasis group. FVC in percent of expected values was similar in the two groups. 
With additional adjustment for smoking, however, only the reduction in FEV1 remained statistically 
significant (delta value -1.6, 95% confidence interval [CI] -2.5 to -0.6%; p=0.002) whereas the 
proportions of individuals with FEV1<80% and FVC<80% of predicted values were not different 
between the two groups. Further adjustment for hs-CRP did not change these results (not shown). 
Moreover, the percentage of subjects with FEV1/FVC ratio<0.70 was increased in psoriasis (21.0 vs. 
16.7%; p<0.001) with odds ratio 1.19 (95% CI 1.02 to 1.38; p=0.02) after adjustment for smoking. 
 
To our knowledge these are the first population-based data on pulmonary function in patients with 
psoriasis. The disease was linked to increased rates of shortness of breath and pneumonia within the 
last 10 years, respectively. After full adjustment psoriasis was associated with a small decrease in 
FEV1 while FVC was not different from the comparison group indicating that the predominant 
pulmonary effect of the disease per se is on airway obstruction (FEV1) rather than FVC. Moreover, 
FEV1/FVC ratio<0.70 compatible with COPD or asthma was more prevalent in the psoriasis group in 
agreement with increased risk of COPD reported in observational studies.2 Although the underlying 
mechanisms are unknown it is notable that smoking and prior pneumonia were more frequently 
reported in the psoriasis group and the disease has been linked to increased risk of serious 
infections, especially respiratory infections.1, 5 It is also tempting to speculate that psoriasis-related 
inflammatory airway injury and remodeling plays a role. Indeed, psoriasis is considered to be an 
interleukin 23/T helper cell 17-driven disease and similar inflammatory mechanisms have been 
implicated in the pathogenesis of airway inflammation.4 
Although epidemiological studies have found increased risk of COPD and asthma2-4 only a single 
report is available on pulmonary function in psoriasis.6 These investigators found reduced FEV1/FVC 
ratio but unaltered FEV1 in subjects with psoriasis (n=69) attending a dermatology clinic compared 
to controls with various other skin diseases.7 In that report, subjects with psoriasis were also 
younger (mean age 42.8 years) than in our study and did not display certain psoriatic phenotype 
characteristics, e.g. increased BMI found in our study.1, 7 Also, self-reported shortness of breath and 
prior pneumonia were not reported.7 We here extend these earlier findings and our results from a 
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with a small but significant reduction of FEV1. Although the magnitude of this reduction was small 
and of questionable clinical significance it is possible that this may contribute to increased shortness 
of breath in subjects with psoriasis.  
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Table 1. Demographic, clinical and spirometric characteristics of the study population. 







Age, years  56.1±13.6 57.0±12.5 0.027
BMI, kg/m2  26.7±4.7 27.2±4.9 <0.001
hs-CRP, mg/L 2.74±5.49 3.12±5.94 0.022
FEV1, % of expected value 94.9±16.4 93.2±16.8 <0.001
FVC, % of expected value 95.8±15.1 95.1±16.6 0.16
FEV1/FVC ratio 0.769±0.085 0.759±0.090 <0.001
Categorical variables n (%) n (%)
Males 8771 (45.6) 528 (45.0) 0.73
Smoking  <0.001
 Never 7542 (41.4) 350 (30.9)
 Previous 3379 (40.1) 535 (47.2)
 Current 1831 (18.5) 248 (21.9)
 Comparison group
              n (%) 
Psoriasis 
n (%) 
    p    OR (95% CI)†  
Pneumonia within the 
last 10 years 
4708 (25.0) 342 (29.7) <0.001 1.21 (1.05;1.38) 0.006
Frequently bothered by 
shortness of breath 
680 (3.6) 61 (5.2) 0.004 1.38 (1.04;1.80) 0.02
FEV1<80% of expected 
value 
2848 (14.9) 199 (17.1) 0.04 1.10 (0.93;1.29) 0.27
FVC<80% of expected 
value 
2353 (12.3) 158 (13.6) 0.21 1.09 (0.91;1.29) 0.36
FEV1/FVC ratio<0.7 3193 (16.7) 244 (21.0) <0.001 1.19 (1.02;1.38) 0.02
 
BMI: body mass index; CI: confidence interval; hs-CRP: high sensitive C-reactive protein; FEV1: forced 
expiratory volume in the first second; FVC: forced vital capacity; SD: standard deviation; OR: Odds 
ra o; CI: confidence interval, †) Values adjusted for smoking 
 
